Previous close | 30.85 |
Open | 30.85 |
Bid | 36.80 |
Ask | 39.50 |
Strike | 100.00 |
Expiry date | 2024-07-19 |
Day's range | 30.85 - 30.85 |
Contract range | N/A |
Volume | |
Open interest | 2.67k |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript May 1, 2024 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome […]
Q1 2024 Sarepta Therapeutics Inc Earnings Call